757903-81-4

Usage

Uses

Used in Organic Synthesis:
3-Pyridinecarboxylic acid, 5,6-dimethyl-(9CI) is used as a building block in organic synthesis for the creation of various biologically active compounds. Its unique structure allows it to be a key component in the development of new molecules with potential applications in various fields.
Used in Pharmaceutical Research:
In pharmaceutical research, 3-Pyridinecarboxylic acid, 5,6-dimethyl-(9CI) is utilized as an intermediate for the synthesis of drugs with therapeutic potential. Its presence in the molecular structure can contribute to the desired pharmacological properties of the final product.
Used in Agricultural and Veterinary Chemicals Production:
3-Pyridinecarboxylic acid, 5,6-dimethyl-(9CI) also serves as an intermediate in the production of agricultural and veterinary chemicals. Its involvement in the synthesis process helps create effective solutions for pest control and other agricultural applications, as well as veterinary medications.
Safety Precautions:
When handling 3-Pyridinecarboxylic acid, 5,6-dimethyl-(9CI), it is crucial to follow all safety guidelines and regulations to ensure the protection of individuals and the environment. Proper precautions should be taken to minimize any potential risks associated with this chemical compound.

Upstream product

• 695-98-7 2,3,5-trimethyl-pyridine 
• 1174028-18-2 5,6-dimethylnicotinic acid methyl ester 
• 41667-95-2 5,6-dichloronicotinic acid 
• 56055-54-0 methyl 2,3-dichloro-pyridine-5-carboxylate 
• 113124-09-7 5,6-dimethyl-3-pyridinecarbonitrile 

Downstream Products

• 118420-53-4 (E)-N-[4-(4-Benzhydryl-piperazin-1-yl)-butyl]-3-(5,6-dimethyl-pyridin-3-yl)-acrylamide 
• 1174028-17-1 5,6-dimethylpyridine-3-carboxaldehyde 
• 583-61-9 2,3-Lutidine 
• 77629-53-9 ethyl 5,6-dimethyl-3-pyridinecarboxylate 

Relevant academic research and scientific papers

THERAPEUTIC AGENT FOR ANXIETY DISORDERS

Provided are an agent for the treatment and/or prophylaxis of an anxiety disorder comprising, as an active ingredient, a thiazole derivative represented by the formula (I) wherein R 1 represents aryl or the like, and R 2 represents pyridyl or the like, or a pharmaceutically acceptable salt thereof, and the like.

Novel compounds

The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.

NOVEL COMPOUNDS

The preseent invention relates to novel retinoid-related orphan receptor gamma(RORγ)modulators and their use in the treatment ofdiseases mediated by RORγ.

NOVEL COMPOUNDS

The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.

THERAPEUTIC AGENT FOR ANXIETY DISORDERS

Provided are an agent for the treatment and/or prophylaxis of an anxiety disorder comprising, as an active ingredient, a thiazole derivative represented by the formula (I) wherein R1 represents aryl or the like, and R2 represents pyridyl or the like, or a pharmaceutically acceptable salt thereof, and the like.

THERAPEUTIC AGENT FOR MOOD DISORDERS

Provided are an agent for the treatment and/or prophylaxis of a mood disorder comprising, as an active ingredient, a thiazole derivative represented by the formula (I) wherein R1 represents aryl or the like, and R2 represents pyridyl or the like, or a pharmaceutically acceptable salt thereof, and the like.

THERAPEUTIC AGENT FOR MOTOR DISORDERS

Provided are an agent for the treatment and/or prophylaxis of a movement disorder, the agent for the treatment and/or prophylaxis wherein the movement disorder is extrapyramidal syndrome, the agent for the treatment and/or prophylaxis wherein the movement disorder is bradykinesia, gait disturbance, dystonia, dyskinesia or tardive dyskinesia, the agent for the treatment and/or prophylaxis wherein the movement disorder is a side effect of L-DOPA and/or dopamine agonist therapy, and the like, each containing a thiazole derivative represented by the formula (I) wherein R1 represents aryl and the like, and R2 represents pyridyl or the like, or a pharmaceutically acceptable salt thereof as an active ingredient.

Acrylamide derivatives as antiallergic agents. 2. Synthesis and structure-activity relationships of N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acrylamides

A new series of 3-(3-pyridyl)acrylamides 16, 17, 19, and 26, and 5-(3-pyridyl)-2,4-pentadienamides 20-25 were prepared and evaluated for their antiallergic activity. Several of these compounds exhibited more potent inhibitory activities than the parent compounds 1a [(E)-N-[4 [4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acrylamide] against the rat passive cutaneous anaphylaxis (PCA) reaction and the enzyme 5-lipoxygenase. Particularly, 4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(6-methyl-3-pyridyl)acrylamide (17p) showed an ED50 value of 3.3 mg/kg po in the rat PCA test, which was one-fifth of ketotifen and oxatomide. As compared with ketotifen and oxatomide, compound 17p (AL-3264) possessed a better balance of antiallergic properties due to inhibition of chemical mediator release, inhibition of 5-lipoxygenase, and antagonism of histamine.